Page last updated: 2024-11-12

ne 21650

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

NE 21650: inhibits isopentenyl diphosphate isomerase; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	9994754
CHEMBL ID	414849
MeSH ID	M0413954

Synonyms (20)

Synonym
ne21650 ,
[2-(2-aminophenyl)-1-hydroxy-1-phosphonoethyl]phosphonic acid
gtpl3167
ne-21650
ne 21650
CHEMBL414849 ,
hydrogen [2-(2-azaniumylphenyl)-1-hydroxy-1-phosphonatoethyl]phosphonate
bdbm50173792
[2-(2-amino-phenyl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acid
2-(2-aminophenyl)-1-hydroxyethane-1,1-diyldiphosphonic acid
Q27087883
78xzc39fr5 ,
p,p'-(2-(2-aminophenyl)-1-hydroxyethylidene)bis(phosphonic acid)
phosphonic acid, p,p'-(2-(2-aminophenyl)-1-hydroxyethylidene)bis-
phosphonic acid, (2-(2-aminophenyl)-1-hydroxyethylidene)bis-
unii-78xzc39fr5
(2-(2-aminophenyl)-1-hydroxy-1-phosphonoethyl)phosphonic acid
427899-21-6
cid 9994754
AKOS040749008

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Farnesyl pyrophosphate synthase	Homo sapiens (human)	IC50 (µMol)	0.1962	0.0002	0.7109	9.3600	AID318593; AID318594
Farnesyl pyrophosphate synthase	Homo sapiens (human)	Ki	0.0340	0.0001	0.2165	1.9000	AID318593; AID318594
H	Trypanosoma brucei	IC50 (µMol)	2.1000	2.1000	2.1000	2.1000	AID254970
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Process	via Protein(s)	Taxonomy
cholesterol biosynthetic process	Farnesyl pyrophosphate synthase	Homo sapiens (human)
geranyl diphosphate biosynthetic process	Farnesyl pyrophosphate synthase	Homo sapiens (human)
farnesyl diphosphate biosynthetic process	Farnesyl pyrophosphate synthase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Process	via Protein(s)	Taxonomy
RNA binding	Farnesyl pyrophosphate synthase	Homo sapiens (human)
protein binding	Farnesyl pyrophosphate synthase	Homo sapiens (human)
metal ion binding	Farnesyl pyrophosphate synthase	Homo sapiens (human)
dimethylallyltranstransferase activity	Farnesyl pyrophosphate synthase	Homo sapiens (human)
geranyltranstransferase activity	Farnesyl pyrophosphate synthase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Process	via Protein(s)	Taxonomy
nucleoplasm	Farnesyl pyrophosphate synthase	Homo sapiens (human)
cytosol	Farnesyl pyrophosphate synthase	Homo sapiens (human)
cytoplasm	Farnesyl pyrophosphate synthase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (12)

Assay ID	Title	Year	Journal	Article
AID349072	Toxicity against human SF268 cells assessed as growth inhibition by broth microdilution method	2008	Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19	Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR investigation.
AID340434	Antimicrobial activity against Dictyostelium discoideum	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Determination of the microscopic equilibrium dissociation constants for risedronate and its analogues reveals two distinct roles for the nitrogen atom in nitrogen-containing bisphosphonate drugs.
AID349070	Inhibition of the ATP-mediated HIV1 reverse transcriptase D67N/K70R/T215F/K219Q mutant catalyzed 3'-azido, 3'-deoxythymidine excision from AZT-terminated DNA primers	2008	Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19	Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR investigation.
AID318594	Inhibition of human recombinant FPPS expressed in Escherichia coli BL21 after 10 mins	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
AID349074	Inhibition of the ATP-mediated HIV1 reverse transcriptase D67N/K70R/T215F/K219Q mutant catalyzed DNA synthesis	2008	Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19	Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR investigation.
AID349073	Toxicity against human NCI-H460 cells assessed as growth inhibition by broth microdilution method	2008	Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19	Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR investigation.
AID318593	Inhibition of human recombinant FPPS expressed in Escherichia coli BL21	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
AID318595	Inhibition of bone resorption in rat assessed as phosphate	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
AID254970	Inhibition of recombinant Trypanosoma brucei soluble vacuolar pyrophosphatase expressed in Escherichia coli	2005	Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19	Bisphosphonate inhibition of the exopolyphosphatase activity of the Trypanosoma brucei soluble vacuolar pyrophosphatase.
AID349071	Toxicity against human MCF7 cells assessed as growth inhibition by broth microdilution method	2008	Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19	Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR investigation.
AID340428	Inhibition of farnesyl diphosphate synthase at 7 nM	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Determination of the microscopic equilibrium dissociation constants for risedronate and its analogues reveals two distinct roles for the nitrogen atom in nitrogen-containing bisphosphonate drugs.
AID1346854	Human isopentenyl-diphosphate Delta-isomerase 1 (Lanosterol biosynthesis pathway)	2002	Biochemical and biophysical research communications, Jan-18, Volume: 290, Issue:2	Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.56 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.36 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
diphosphoric acid diphosphoric acid : An acyclic phosphorus acid anhydride obtained by condensation of two molecules of phosphoric acid.	2.04	1	acyclic phosphorus acid anhydride; phosphorus oxoacid	Escherichia coli metabolite
alendronate alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.	2.72	3	1,1-bis(phosphonic acid); primary amino compound	bone density conservation agent; EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
incadronate [no description available]	2.02	1	1,1-bis(phosphonic acid)
pamidronate [no description available]	2.04	1	phosphonoacetic acid
risedronic acid Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.	2.73	3	pyridines
2-(2-pyridyl)ethylidine-1,1-bisphosphonate 2-(2-pyridyl)ethylidine-1,1-bisphosphonate: inhibits hypercalciuria	2.04	1
ibandronic acid Ibandronic Acid: Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.	2.04	1
zoledronic acid Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.	2.44	2	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent
6-amino-1-hydroxyhexane-1,1-diphosphonate 6-amino-1-hydroxyhexane-1,1-diphosphonate: used for therapy of Paget's disease of bone & malignant hypercalcaemia	2.44	2	1,1-bis(phosphonic acid)
ne 58051 NE 58051: inhibits tumor cell adhesion to extracellular matrices; structure in first source	2.44	2
1-hydroxypentane-1,1-bisphosphonate [no description available]	2.02	1
cimadronate cimadronate: increases serum 1,25-dihydroxyvitamin D in rats via stimulating renal 1-hydroxylase activity; structure given in first source	2.04	1
ne 10790 [no description available]	2.04	1

Condition	Indicated	Relationship Strength	Studies	Trials
African Sleeping Sickness [description not available]	0	2.02	1	0
Trypanosomiasis, African A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces African sleeping sickness. Nagana is a rapidly fatal trypanosomiasis of horses and other animals.	0	2.02	1	0

chemdatabank.com